Novopyxis, founded by a team of MIT-trained scientists, is an award-winning biotechnology company focused on developing therapeutics and innovative medical devices. Their core mission is to leverage advanced mathematical and physics principles to overcome challenges in drug design and delivery. The company's flagship product is a therapeutic that activates the AT2R anti-inflammatory receptor, offering cardioprotective and neuroprotective benefits. This therapeutic has been validated across various models and recently received orphan designation for treating Pediatric Cardiomyopathy.

Notable affiliations include support from NASA, the Veteran’s Association, and Brigham and Women’s Hospital. Novopyxis has achieved significant milestones, including the development of proprietary algorithms for protein structure generation and drug design using knot theory and fluid physics. Their impact is marked by advancements in medical technology and the potential to address critical health issues with innovative solutions.